4-amino-2-(4-morpholinyl)-1,3-thiazole-5-carbonitrile | 1069114-63-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-amino-2-(4-morpholinyl)-1,3-thiazole-5-carbonitrile
• 英文别名: 4-amino-2-morpholin-4-yl-1,3-thiazole-5-carbonitrile
• CAS: 1069114-63-1
• 化学式: C₈H₁₀N₄OS
• 分子量: 210.26
• InChiKey: UIYOZICJTFXJEZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  103
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-amino-2-(4-morpholinyl)-1,3-thiazole-5-carbonitrile 在 亚硝酸特丁酯 、 copper(ll) bromide 作用下， 以 乙腈 为溶剂， 以76%的产率得到4-bromo-2-morpholino-1,3-thiazole-5-carbonitrile
  参考文献：
  名称：

  4-Bromo-2-(piperidin-1-yl)thiazol-5-yl-phenyl methanone (12b) inhibits Na+/K+-ATPase and Ras oncogene activity in cancer cells

  摘要：

  The in vitro growth inhibitory activity of 26 thiazoles (including 4-halogeno-2,5-disubtituted-1,3-thiazoles) and 5 thienothiazoles was assessed on a panel of 6 human cancer cell lines, including glioma cell lines. (4-Chloro-2-(piperidin-1-yl)thiazol-5-yl)(phenyl)methanone (12a) and (4-bromo-2-(piperidin-1-yl)thiazol-5-yl)(phenyl)methanone (12b) displayed similar to 10 times greater in vitro growth inhibitory activity than perillyl alcohol (POH), which therapeutically benefits glioma patients through the inhibition of both alpha-1 Na+/K+-ATPase (NAK) and Ras oncogene activity. The in vitro cytostatic activities (as revealed by quantitative videomicroscopy) displayed by 12a and 12b were independent of the intrinsic resistance to pro-apoptotic stimuli associated with cancer cells. Compounds 12a and 12b displayed relatively similar inhibitory activities on purified guinea pig brain preparations that mainly express NAK alpha-2 and alpha-3 subunits, whereas only compound 12b was efficacious against purified guinea pig kidney preparations that mainly express the NAK alpha-1 subunit, which is also expressed in gliomas, melanomas and non-small-cell lung cancers NSCLCs. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.01.046
• 作为产物：
  描述：

  在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 生成 4-amino-2-(4-morpholinyl)-1,3-thiazole-5-carbonitrile
  参考文献：
  名称：

  Synthesis of substituted [1,3]thiazolo[4,5-b]pyridines and [1,3]thiazolo[4,5-d][1,2,3]triazines

  摘要：

  In this work, we described an easy preparation Of substituted 4-amino-5-cyano-1,3-thiazoles. These compounds have been used as starting materials to obtain two classes of compounds. New substituted [1,3]thiazolo[4,5-e]pyridines were synthesized in one step via Friedlander reaction. Diazotation of 4-amino-5-cyano-1,3-thiazoles afforded 4-chloro[1,3]thiazolo[4,5-d][1,2,3]triazines in one step. The later Was substituted by a secondary amine to obtain substituted 4-amino[1,3]thiazolo[4,5-d][1,2,3]triazines. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2008.07.017

文献信息

• One-pot synthesis of new 2,4,5-trisubstituted 1,3-thiazoles and 1,3-selenazoles
  作者：David Thomae、Enrico Perspicace、Zhanjie Xu、Dorothée Henryon、Serge Schneider、Stéphanie Hesse、Gilbert Kirsch、Pierre Seck

  DOI：10.1016/j.tet.2009.01.104

  日期：2009.4

  In this work, we describe the synthesis of new 2,4,5-trisubstituted-1,3-thiazoles and 1,3-selenazole achieved by an easy one-pot four-step procedure. Expected compounds were obtained in good yield from dimethyl cyanodithioimidocarbonate, which was the common starting material for the preparation of all 1,3-thiazoles and 1,3-selenazoles. Chemical diversity was introduced on thiazole and selenazole rings

  在这项工作中，我们描述了通过简单的一锅四步法实现的新2,4,5-三取代-1,3-噻唑和1,3-硒唑的合成。从氰基二硫代亚氨基碳酸二甲酯中可以以高收率获得预期的化合物，后者是制备所有1,3-噻唑和1,3-硒唑的常用原料。通过改变所用的胺和活化的卤化物，在噻唑和硒唑环上引入了化学多样性。
• [EN] THIAZOLOPYRIMIDINONE DERIVATIVES AS PI3 KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE THIAZOLOPYRIMIDINONE COMME INHIBITEURS DE LA KINASE PI3
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2010135504A1

  公开（公告）日：2010-11-25

  This invention relates to the use of thiazolopyrimidinone derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3' OH kinase family (hereinafter PI3 kinases), suitably, PI3Kα, PI3Kδ, PI3Kβ, and/or PI3Kγ. Suitably, the present invention relates to the use of thiazolopyrimidinones in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3Kβ selective thiazolopyrimidinones compounds for treating cancer.

  这项发明涉及噻唑吡咯嘧啶酮衍生物在调节磷脂酰肌醇3' OH激酶家族（以下简称PI3激酶）的活性或功能，特别是抑制其活性或功能方面的用途，适当地，PI3Kα、PI3Kδ、PI3Kβ和/或PI3Kγ。适当地，本发明涉及噻唑吡咯嘧啶酮在治疗以下一种或多种疾病状态中的用途：自身免疫性疾病、炎症性疾病、心血管疾病、神经退行性疾病、过敏、哮喘、胰腺炎、多器官功能衰竭、肾脏疾病、血小板聚集、癌症、精子活动力、移植排斥、移植物排斥和肺部损伤。更适当地，本发明涉及PI3Kβ选择性噻唑吡咯嘧啶酮化合物用于治疗癌症。
• THIAZOLOPYRIMIDINONE DERIVATIVES AS PI3 KINASE INHIBITORS
  申请人：Lin Hong

  公开号：US20120053147A1

  公开（公告）日：2012-03-01

  This invention relates to novel compounds of formula (I): and derivatives thereof useful for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3′ OH kinase family (hereinafter PI3 kinases), suitably, PI3Kα, PI3K}, PI3Kβ, and/or PI3Kγ.

  本发明涉及公式（I）的新化合物及其衍生物，可用于调节磷脂酰肌醇3′ OH激酶家族（以下简称PI3激酶）的活性或功能，特别是适用于PI3Kα，PI3K}，PI3Kβ和/或PI3Kγ的抑制。
• Thiazolopyrimidinone derivatives as PI3 kinase inhibitors
  申请人：Lin Hong

  公开号：US08410095B2

  公开（公告）日：2013-04-02

  This invention relates to novel compounds of formula (I): and derivatives thereof useful for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3′ OH kinase family (hereinafter PI3 kinases), suitably, PI3Kα, PI3Kδ, PI3Kβ, and/or PI3Kγ.

  本发明涉及式（I）的新型化合物及其衍生物，用于调节，特别是抑制磷脂酰肌醇3'-OH激酶家族（以下简称PI3激酶），适用于PI3Kα，PI3Kδ，PI3Kβ和/或PI3Kγ的活性或功能。
• Rational Design, Synthesis, and SAR of a Novel Thiazolopyrimidinone Series of Selective PI3K-beta Inhibitors
  作者：Hong Lin、Mark J. Schulz、Ren Xie、Jin Zeng、Juan I. Luengo、Michael D. Squire、Rosanna Tedesco、Junya Qu、Karl Erhard、James F. Mack、Kaushik Raha、Ramona Plant、Cynthia M. Rominger、Jennifer L. Ariazi、Christian S. Sherk、Michael D. Schaber、Jeanelle McSurdy-Freed、Michael D. Spengler、Charles B. Davis、Mary Ann Hardwicke、Ralph A. Rivero

  DOI：10.1021/ml300045b

  日期：2012.7.12

  A novel thiazolopyrimidinone series of PI3K-beta selective inhibitors has been identified. This chemotype has provided an excellent tool compound, 18, that showed potent growth inhibition in the PTEN-deficient breast cancer cell line MDA-MB-468 Under anchorage independent conditions, and it also demonstrated pharmacodynamic effects and efficacy in a PTEN-deficient prostate cancer PC-3 xenograft mouse model.